Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;83(5):1523-1526.
doi: 10.1016/j.jaad.2020.06.1014. Epub 2020 Jul 2.

The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

Maha N Syed  1 , Daniel B Shin  1 , Marilyn T Wan  1 , Kevin L Winthrop  2 , Joel M Gelfand  3
Affiliations

The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic

Maha N Syed et al. J Am Acad Dermatol. 2020 Nov.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Meta-estimate of respiratory tract infections from prescribing information adverse events tables (includes “upper respiratory tract infections,” “nasopharyngitis,” “respiratory tract infection (viral, bacterial and unspecified),” “influenza,” “sinusitis (including acute),” “pharyngitis (including viral),” “tonsillitis,” and “rhinitis”). Doses used in this meta-estimate were guselkumab 100 mg, risankizumab 150 mg, and tildrakizumab 100 mg for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The size of the square corresponds to the relative weight assigned in the pooled analysis, and the horizontal lines indicate the 95% CI. The diamond denotes the overall effect size, and the lateral tips of the diamond indicate the associated CI. CI, Confidence interval; REML, restricted maximum likelihood.
Fig 2
Fig 2
Meta-estimate of respiratory tract infections from clinicaltrials.gov in phase 3 randomized controlled trials that were submitted for US Food and Drug Administration approval (includes “upper respiratory tract infections,” “viral upper respiratory tract infections,” “influenza,” “chylothorax,” “sinusitis,” “bronchitis,” “tonsillitis,” “nasopharyngitis,” and “pneumonia”). Doses used in this meta-estimate were guselkumab 100 mg, risankizumab 150 mg, and tildrakizumab 100 mg for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The size of the square corresponds to the relative weight assigned in the pooled analysis, and the horizontal lines indicate the 95% confidence interval. The diamond denotes the overall effect size, and the lateral tips of the diamond indicate the associated CI. reSURFACE-2 adverse events were verified from the sponsor because clinicaltrials.gov adverse events were reported in the sum of the extended trial period. CI, Confidence interval; REML, restricted maximum likelihood.
See this image and copyright information in PMC

References

    1. Wan M.T., Shin D.B., Winthrop K.L., Gelfand J.M. The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83:677–679. - PMC - PubMed
    1. Yannam G.R., Gutti T., Poluektova L.Y. IL-23 in infections, inflammation, autoimmunity and cancer: possible role in HIV-1 and AIDS. J Neuroimmune Pharmacol. 2012;7:95–112. - PMC - PubMed
    1. Kamata M., Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21:1690. - PMC - PubMed
    1. Damiani G., Pacifico A., Bragazzi N.L., Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration. Dermatol Ther. 2020:e13475. - PMC - PubMed
    1. Benhadou F., Del Marmol V. Improvement of SARS-CoV2 symptoms following guselkumab injection in a psoriatic patient. J Eur Acad Dermatol Venereol. 2020 doi: 10.1111/jdv.16590. - DOI - PMC - PubMed

Publication types

MeSH terms